Drug
Bay2757556
Bay2757556: highest development phase Phase 2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| BAY2757556 (Larotrectinib, Vitrakvi) NCT02576431 | Phase 2 | Solid Tumors Harboring NTRK Fusion |
Latest
No recent events.
Follow Bay2757556 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.